Myovant Sciences’ Oral Therapy for Advanced Prostate Cancer Wins FDA Approval

Myovant Sciences’ oral hormone therapy Orgovyx (relugolix) was approved by the FDA for treatment of men with advanced prostate cancer.

A form of androgen deprivation therapy, Orgovyx lowers hormone levels that enable prostate cancer cells to grow. Unlike other treatments in this class, the drug doesn’t have to be injected or implanted under the skin.

The oral formulation “may eliminate some patients’ need to visit the clinic for treatments that require administration by a healthcare provider,” said Richard Pazdur, director of the FDA’s Oncology Center of Excellence.